Nanjing Hicin Pharmaceutical Co Ltd (300584) - Net Assets
Based on the latest financial reports, Nanjing Hicin Pharmaceutical Co Ltd (300584) has net assets worth CN¥1.12 Billion CNY (≈ $163.33 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.53 Billion ≈ $224.15 Million USD) and total liabilities (CN¥415.66 Million ≈ $60.82 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Nanjing Hicin Pharmaceutical Co Ltd to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.12 Billion |
| % of Total Assets | 72.86% |
| Annual Growth Rate | 17.67% |
| 5-Year Change | 15.96% |
| 10-Year Change | 298.33% |
| Growth Volatility | 22.23 |
Nanjing Hicin Pharmaceutical Co Ltd - Net Assets Trend (2012–2025)
This chart illustrates how Nanjing Hicin Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Nanjing Hicin Pharmaceutical Co Ltd balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Nanjing Hicin Pharmaceutical Co Ltd (2012–2025)
The table below shows the annual net assets of Nanjing Hicin Pharmaceutical Co Ltd from 2012 to 2025. For live valuation and market cap data, see 300584 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.10 Billion ≈ $160.94 Million |
+5.94% |
| 2024-12-31 | CN¥1.04 Billion ≈ $151.92 Million |
+5.13% |
| 2023-12-31 | CN¥987.50 Million ≈ $144.50 Million |
+3.89% |
| 2022-12-31 | CN¥950.57 Million ≈ $139.10 Million |
+0.22% |
| 2021-12-31 | CN¥948.48 Million ≈ $138.79 Million |
+39.69% |
| 2020-12-31 | CN¥678.97 Million ≈ $99.35 Million |
+3.82% |
| 2019-12-31 | CN¥653.98 Million ≈ $95.70 Million |
+12.58% |
| 2018-12-31 | CN¥580.93 Million ≈ $85.01 Million |
+12.22% |
| 2017-12-31 | CN¥517.68 Million ≈ $75.75 Million |
+87.49% |
| 2016-12-31 | CN¥276.11 Million ≈ $40.40 Million |
+17.46% |
| 2015-12-31 | CN¥235.08 Million ≈ $34.40 Million |
+17.45% |
| 2014-12-31 | CN¥200.15 Million ≈ $29.29 Million |
+20.62% |
| 2013-12-31 | CN¥165.93 Million ≈ $24.28 Million |
+25.09% |
| 2012-12-31 | CN¥132.65 Million ≈ $19.41 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Nanjing Hicin Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1738.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥660.77 Million | 62.73% |
| Other Components | CN¥392.50 Million | 37.27% |
| Total Equity | CN¥1.05 Billion | 100.00% |
Nanjing Hicin Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Nanjing Hicin Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Embracer Group AB Series B
LSE:0GFE
|
$650.60 Million |
|
Shandong Shuangyi Technology Co Ltd
SHE:300690
|
$650.87 Million |
|
Svenska Cellulosa Aktiebolaget SCA (publ)
ST:SCA-A
|
$651.07 Million |
|
Sri Trang Agro-Industry Public Company Limited
BK:STA-R
|
$651.11 Million |
|
TPG RE Finance Trust Inc
NYSE:TRTX
|
$650.35 Million |
|
Zhejiang Feida Environmental Science & Technology Co Ltd
SHG:600526
|
$650.23 Million |
|
Talkspace Inc
NASDAQ:TALK
|
$649.77 Million |
|
Jiangsu Yike Food Group Co.Ltd
SHE:301116
|
$649.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nanjing Hicin Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,022,936,243 to 1,053,270,438, a change of 30,334,195 (3.0%).
- Net income of 42,058,385 contributed positively to equity growth.
- Dividend payments of 19,504,657 reduced retained earnings.
- Other comprehensive income decreased equity by 60,735,963.
- Other factors increased equity by 68,516,430.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥42.06 Million | +3.99% |
| Dividends Paid | CN¥19.50 Million | -1.85% |
| Other Comprehensive Income | CN¥-60.74 Million | -5.77% |
| Other Changes | CN¥68.52 Million | +6.51% |
| Total Change | CN¥- | 2.97% |
Book Value vs Market Value Analysis
This analysis compares Nanjing Hicin Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.22x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 25.36x to 4.22x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥1.46 | CN¥37.05 | x |
| 2013-12-31 | CN¥1.83 | CN¥37.05 | x |
| 2014-12-31 | CN¥2.22 | CN¥37.05 | x |
| 2015-12-31 | CN¥2.60 | CN¥37.05 | x |
| 2016-12-31 | CN¥3.05 | CN¥37.05 | x |
| 2017-12-31 | CN¥4.41 | CN¥37.05 | x |
| 2018-12-31 | CN¥4.84 | CN¥37.05 | x |
| 2019-12-31 | CN¥5.45 | CN¥37.05 | x |
| 2020-12-31 | CN¥5.67 | CN¥37.05 | x |
| 2021-12-31 | CN¥7.92 | CN¥37.05 | x |
| 2022-12-31 | CN¥7.92 | CN¥37.05 | x |
| 2023-12-31 | CN¥8.23 | CN¥37.05 | x |
| 2024-12-31 | CN¥8.52 | CN¥37.05 | x |
| 2025-12-31 | CN¥8.78 | CN¥37.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nanjing Hicin Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.27%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.45x
- Recent ROE (3.99%) is below the historical average (13.22%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 19.29% | 17.30% | 0.78x | 1.44x | CN¥12.33 Million |
| 2013 | 20.06% | 19.64% | 0.70x | 1.45x | CN¥16.69 Million |
| 2014 | 17.09% | 17.31% | 0.67x | 1.47x | CN¥14.20 Million |
| 2015 | 17.16% | 18.25% | 0.68x | 1.37x | CN¥16.82 Million |
| 2016 | 16.38% | 16.11% | 0.76x | 1.34x | CN¥17.63 Million |
| 2017 | 12.67% | 14.42% | 0.72x | 1.22x | CN¥13.83 Million |
| 2018 | 14.33% | 11.69% | 0.90x | 1.37x | CN¥25.13 Million |
| 2019 | 14.87% | 10.52% | 1.06x | 1.33x | CN¥31.85 Million |
| 2020 | 8.12% | 7.82% | 0.78x | 1.33x | CN¥-12.75 Million |
| 2021 | 30.08% | 49.43% | 0.44x | 1.37x | CN¥190.85 Million |
| 2022 | 3.41% | 6.16% | 0.41x | 1.36x | CN¥-62.61 Million |
| 2023 | 3.68% | 7.01% | 0.37x | 1.43x | CN¥-62.43 Million |
| 2024 | 3.93% | 7.97% | 0.34x | 1.43x | CN¥-62.08 Million |
| 2025 | 3.99% | 6.27% | 0.44x | 1.45x | CN¥-63.27 Million |
Industry Comparison
This section compares Nanjing Hicin Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,553,112,060
- Average return on equity (ROE) among peers: 6.42%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nanjing Hicin Pharmaceutical Co Ltd (300584) | CN¥1.12 Billion | 19.29% | 0.37x | $650.59 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.06 Billion | 5.59% | 4.55x | $627.58 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $638.89 Million | 0.88% | 0.70x | $407.99 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.02 Billion | 12.46% | 0.13x | $4.67 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $4.81 Billion | 12.94% | 0.68x | $2.65 Billion |
| Wedge Industrial Co Ltd (000534) | $549.14 Million | 1.31% | 0.01x | $2.68 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $893.64 Million | 25.78% | 0.79x | $13.00 Billion |
| Hainan Haiyao Co Ltd (000566) | $1.73 Billion | 9.42% | 1.13x | $812.54 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $278.65 Million | -21.41% | 1.49x | $365.84 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $3.92 Billion | 4.44% | 2.20x | $994.02 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $635.85 Million | 12.83% | 0.33x | $3.05 Billion |
About Nanjing Hicin Pharmaceutical Co Ltd
Nanjing Hicin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of chemical preparations, APIs, and intermediates. The company's products include landiolol hydrochloride, rivaroxaban, tigecycline, torasemide, cefuroxime sodium, ceftriaxone hydrochloride, ganciclovir sodium, adenosine monophosphate, and adenosine monophosphate for … Read more